Mereo BioPharma Group plc
Moat Score — Mereo BioPharma Group plc
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Mereo holds patents and clinical data packages on setrusumab, alvelestat, and its other rare-disease candidates, but much of that IP value has already been monetized away through out-licensing rather than retained in-house. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a small clinical-stage biotech, Mereo has no manufacturing or development cost advantage versus larger pharmaceutical partners who actually fund late-stage trials. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved or commercially sold products, Mereo has no pricing power of its own; any future pricing is set by partners like Ultragenyx and AstraZeneca upon commercialization. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Drug development and licensing exhibit no network effect between patients, physicians, or partners. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Signed licensing agreements with Ultragenyx, AstraZeneca, and others create contractual continuity, but Mereo itself could be bypassed if a partner chooses to in-license a competing rare-disease asset instead. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Rare diseases like osteogenesis imperfecta and AATD-associated lung disease have small enough patient populations that large pharma companies often prefer to in-license rather than build competing programs, giving focused players like Mereo a defensible niche. |